Skip to search formSkip to main contentSkip to account menu

omalizumab

Known as: Immunoglobulin G, anti-(human immunoglobulin E Fc region)(human-mouse monoclonal E25 clone pSVIE26 gamma-chain), disulfide with human-mouse monoclonal E25 clone pSVIE26 kappa-chain, dimer, Omalizumab [Chemical/Ingredient], Ig gamma-1 chain C region 
An anti-IgE, recombinant, humanized monoclonal antibody which specifically binds to the C epsilon3 domain of IMMUNOGLOBULIN E, the site of high… 
National Institutes of Health

Related topics

Related topics

9 relations

Broader (2)

Anti-Allergic AgentsAnti-Asthmatic Agents
In Bloodantigen bindingaspects of radiation effectsomalizumab 150 MG Injection [Xolair]

Narrower (1)

Xolair

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
What the physicians should know about mast cells, dendritic cells, urticaria, and omalizumab during COVID‐19 or asymptomatic infections due to SARS‐CoV‐2?
Coronavirus disease (COVID‐19) pandemic presents several dermatological manifestations described in the present indexed… 
Review
2015
Review
2015
Biological drugs in ANCA-associated vasculitis.
2013
2013
Sequential combined therapy with omalizumab and rituximab: a new approach to severe atopic dermatitis.
BACKGROUND Atopic dermatitis (AD) is a common chronic skin disease, and a significant percentage of AD patients have severe forms… 
2009
2009
Adherence and persistence with omalizumab and fluticasone/salmeterol within a managed care population.
Asthma control requires adherence with pharmacologic therapy. A medication's mode of delivery may affect adherence. The purpose… 
Review
2008
Review
2008
New approaches to managing asthma: a US perspective
Despite remarkable advances in diagnosis and long-term management, asthma remains a serious public health concern. Newly updated… 
2008
2008
Effectiveness of omalizumab in a patient with severe asthma and atopic dermatitis.
The anti-IgE antibody omalizumab is currently indicated in severe asthma not controlled by standard drug therapy. Recently, new… 
2007
2007
Omalizumab reverses the phenotypic and functional effects of IgE-enhanced Fc epsilonRI on human skin mast cells.
The dramatic effects of the anti-IgE mAb omalizumab to lower free IgE levels and Fc epsilonRI levels on basophils contrast with… 
Review
2006
Review
2006
Off-label uses of biologic agents in dermatology: a 2006 update.
Review
2005
Review
2005
Omalizumab: a recombinant humanized monoclonal IgE-blocking antibody.
Omalizumab (Xolair) is a recombinant humanized monoclonal antibody that blocks the high-affinity Fc receptor of immunoglobulin E… 
2003
2003
Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis.
Two randomized, placebo-controlled, double-blind studies have shown clinical benefit with omalizumab (Xolair), a recombinant… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)